TY - JOUR
T1 - Cell death assays for drug discovery
AU - Kepp, Oliver
AU - Galluzzi, Lorenzo
AU - Lipinski, Marta
AU - Yuan, Junying
AU - Kroemer, Guido
N1 - Funding Information:
G.K. is supported by the Ligue Nationale contre le Cancer (Equipes labellisée), the Agence Nationale pour la Recherche (ANR), the European Commission (Active p53, Apo-Sys, ChemoRes, ApopTrain and ArtForce), the Fondation pour la Recherche Médicale (FRM), the Institut National du Cancer (INCa), Cancéropôle Ile-de-France and the AXA Chair for Longevity Research. J.Y. is supported by a US National Institutes of Health Director’s Pioneer Award, grants from the National Institute of Aging (USA) and the National Cancer Institute (USA). We are indebted to S. Shen for providing fluorescence microscopy images.
PY - 2011/3/1
Y1 - 2011/3/1
N2 - Cell death has an important role in many human diseases, and strategies aimed at modulating the associated pathways have been successfully applied to treat various disorders. Indeed, several clinically promising cytotoxic and cytoprotective agents with potential applications in cancer, ischaemic and neurodegenerative diseases have recently been identified by high-throughput screening (HTS), based on appropriate cell death assays. Given that different cell death modalities may be dysregulated in different diseases, it is becoming increasingly clear that such assays need to not only quantify the extent of cell death, but they must also be able to distinguish between the various pathways. Here, we systematically describe approaches to accurately quantify distinct cell death pathways, discuss their advantages and pitfalls, and focus on those techniques that are amenable to HTS.
AB - Cell death has an important role in many human diseases, and strategies aimed at modulating the associated pathways have been successfully applied to treat various disorders. Indeed, several clinically promising cytotoxic and cytoprotective agents with potential applications in cancer, ischaemic and neurodegenerative diseases have recently been identified by high-throughput screening (HTS), based on appropriate cell death assays. Given that different cell death modalities may be dysregulated in different diseases, it is becoming increasingly clear that such assays need to not only quantify the extent of cell death, but they must also be able to distinguish between the various pathways. Here, we systematically describe approaches to accurately quantify distinct cell death pathways, discuss their advantages and pitfalls, and focus on those techniques that are amenable to HTS.
UR - http://www.scopus.com/inward/record.url?scp=79952122944&partnerID=8YFLogxK
U2 - 10.1038/nrd3373
DO - 10.1038/nrd3373
M3 - Review article
C2 - 21358741
AN - SCOPUS:79952122944
SN - 1474-1776
VL - 10
SP - 221
EP - 237
JO - Nature Reviews Drug Discovery
JF - Nature Reviews Drug Discovery
IS - 3
ER -